A Strategy for Combating Melanoma with Oncogenic c-Myc Inhibitors and Targeted Nanotherapy

References

• Gearhart J , PashosEE , PrasadMK . Pluripotency redux – advances in stem-cell research . N. Engl. J. Med.357 , 1469 – 1472 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Lüscher B . Function and regulation of the transcription factors of the Myc/Max/Mad network . Gene277 , 1 – 14 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Cotterman R , JinVX , KrigSRet al. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor . Cancer Res.68 ( 23 ), 9654 – 9662 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Schlagbauer-Wadl H , GriffioenM , van ElsasAet al. Influence of increased c-Myc expression on the growth characteristics of human melanoma . J. Invest. Dermatol.112 ( 3 ), 332 – 336 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Kraehn GM , UtikalJ , UdartMet al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases . Br. J. Cancer84 ( 1 ), 72 – 79 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Chana JS , GroverR , WilsonGDet al. The prognostic importance of c-myc oncogene expression in head and neck melanoma . Ann. Plast. Surg.47 ( 2 ), 172 – 177 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Nair SK , BurleySK . X-ray structures of Myc–Max and Mad–Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors . Cell112 ( 2 ), 193 – 205 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• D’Agnano I , ValentiniIA , FornariCet al. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels . Oncogene20 ( 22 ), 2814 – 2825 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Chen Z , ZengH , GuoYet al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc . J. Exp. Clin. Cancer Res.29 , 151 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Soucek L , JuckerRL , PanacchiaR , RicordyF , TatòSN . Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis . Cancer Res.62 ( 12 ), 3507 – 3510 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Berg T , CohenSB , DesharnaisJet al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts . Proc. Natl Acad. Sci. USA99 ( 6 ), 3830 – 3835 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Yin X , GiapC , LazoJS , ProchownikEV . Low molecular weight inhibitors of Myc–Max interaction and function . Oncogene22 ( 40 ), 6151 – 6159 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Mustata G , FollisAV , HammoudehDIet al. Discovery of novel Myc–Max heterodimer disruptors with a three-dimensional pharmacophore model . J. Med. Chem.52 ( 5 ), 1247 – 1250 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Prochownik EV , GiapC , LazoJS , YinX . US7026343: Improved low molecular weight myc–max inhibitors . ( 2006 ).
   Google Scholar
• Wang H , HammoudehDI , FollisAVet al. Improved low molecular weight Myc–Max inhibitors . Mol. Cancer Ther.6 ( 9 ), 2399 – 2408 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Lin CP , LiuJD , ChowJM , Liu , CR , LiuHE . Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells . Anticancer Drugs18 ( 2 ), 161 – 170 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Caruthers SD , CyrusT , WinterPM , WicklineSA , LanzaGM . Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis . Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.1 ( 3 ), 311 – 323 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Pan D , SanyalN , SchmiederAHet al. Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug . Nanomedicine7 ( 10 ), 1507 – 1519 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Burke J , DennisE . Phospholipase A2 biochemistry. phospholipase A2 biochemistry . Cardiovasc. Drugs Ther.23 , 49 – 59 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Zhou HF , YanH , SenpanAet al. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles . Biomaterials33 ( 33 ), 8632 – 8640 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Arik D , DuvdevaniR , ShapiroI , ElmannA , FinkelsteinE , HoffmanA . The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration . J. Control. Release126 , 1 – 9 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Dahan A , DuvdevaniR , DvirE , ElmannA , HoffmanA . A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin–lecithin conjugate . J. Control. Release119 , 86 – 93 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Davidsen J , J⊘rgensenK , AndresenTL , MouritsenOG . Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue . Biochim. Biophys. Acta1609 ( 1 ), 95 – 101 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Andresen TL , DavidsenJ , BegtrupM , MouritsenOG , J⊘rgensenK . Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome forming prodrugs . J. Med. Chem.47 ( 7 ), 1694 – 1703 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Jensen SS , AndresenTL , DavidsenJet al. Secretory phospholipase A2 as tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer ether lipids . Mol. Cancer Ther.3 ( 11 ), 1451 – 1458 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Andresen TL , JensenSS , KaasgaardT , J⊘rgensenK . Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2 . Curr. Drug Deliv.2 ( 4 ), 353 – 362 ( 2005 ).
   PubMedGoogle Scholar
• Peters G , M⊘llerM , J⊘rgensenK , RönnholmP , MikkelsenM , AndresenT . Secretory phospholipase A2 hydrolysis of phospholipid analogues is dependent on water accessibility to the active site . J. Am. Chem. Soc.129 ( 17 ), 5451 – 5461 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Pan D , SchmiederAH , WangKet al. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β3-targeted theranostic nanoparticles. . Theranostics.4 ( 6 ), 565 – 578 ( 2014 ).
   PubMed Web of Science ®Google Scholar